Strategic alliance for atopic dermatitis and psoriasis

0

LEO Pharma entered a strategic partnership with AstraZeneca to explore potential new medicines for atopic dermatitis and psoriasis. LEO Pharma acquired the global licence to tralokinumab in skin diseases and the exclusive licence to brodalumab in Europe. Tralokinumab is a potential new medicine, an anti-IL-13 monoclonal antibody, that has completed a Phase IIb study for the treatment of patients with atopic dermatitis. Brodalumab is an IL-17 receptor monoclonal antibody under regulatory review for patients with moderate-to-severe plaque psoriasis. AstraZeneca will manufacture and supply tralokinumab to LEO Pharma. AstraZeneca will retain all rights to tralokinumab in respiratory disease and any other indications outside of dermatology.

SHARE

LEAVE A REPLY

Please enter your comment!
Please enter your name here